Arcus Biosciences Inc (RCUS) stock saw a decline, ending the day at $15.31 which represents a decrease of $-0.08 or -0.52% from the prior close of $15.39. The stock opened at $15.19 and touched a low ...

Arcus Biosciences has announced a clinical trial partnership with AstraZeneca to assess the combination of casdatifan (AB521) ...

FixMap is an “M&A machine” and the leading player in the Polish fiber-to-the-home (FTTH) market by far, thanks to the ...

DTCP has invested in Atlantic Hub, a data center developer in Ireland, spotting an opportunity away from more well-trodden ...

US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer ...

Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC ...

Arcus Power, an energy intelligence company, today announced a strategic partnership with weather tech pioneer Climavision, ...

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in ...

Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdatifan leading the way. See why I rate RCUS ...

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform ...

Arcus Hunting, LLC has appointed Matt Kinamore as senior director of product development and category management. In this ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on RCUS stock, giving a Buy rating on September 16. Daina ...